Kisspeptin owes its name to a chocolate. In 1996, a research team in Hershey, Pennsylvania, went looking for a gene that stopped cancer from spreading. When they found a promising candidate, they needed a label. They took the “KI” from Hershey, the town synonymous with the Hershey’s Kiss, added “SS-1” for the suppressor sequence they were tracking, and called it KiSS-1. Nobody in that lab was thinking about hormones or puberty. They were thinking about melanoma. It would take years, and a jump between two entirely separate fields of biology, before anyone realised what they had actually stumbled onto.
A cancer gene with an odd name
The founding paper is easy to cite. Lee, Miele, Hicks, Phillips, Trent, Weissman and Welch published “KiSS-1, a novel human malignant melanoma metastasis-suppressor gene” in the Journal of the National Cancer Institute in 1996 (volume 88, pages 1731-1737). The work came out of the Pennsylvania State University College of Medicine in Hershey.
The method was elegant. The researchers introduced human chromosome 6 into aggressive C8161 melanoma cells and watched their ability to metastasise collapse. Something on that chromosome was switching off the spread. Hunting through the suppressed cells, they isolated a novel cDNA that appeared only in the non-metastatic lines. That was KiSS-1. At this stage it was purely a cancer-biology story: a metastasis suppressor, function largely unknown, sitting in a handful of papers read mostly by oncologists.
The orphan receptor that changed everything
The turning point came in 2001. For years, pharmacologists had been sitting on an “orphan” receptor called GPR54, a G-protein-coupled receptor with no known partner. Deorphanising these receptors, finding the molecule that actually binds them, was a busy sub-industry of the era. Three groups converged on the same answer that year, with reports from Kotani and colleagues, Muir and colleagues, and Ohtaki and colleagues, the last published in Nature (volume 411, pages 613-617). The natural ligand for GPR54 turned out to be the product of the KiSS-1 gene.
Here the peptide chemistry matters. The KISS1 gene encodes a 145-amino-acid precursor, which is cleaved and amidated down to a 54-amino-acid peptide. Because of its origin in a metastasis gene, this peptide was first named metastin; it is now more commonly called kisspeptin-54. Crucially, the researchers found that the biological punch lived in the tail end of the molecule. Shorter fragments cut from the C-terminus, of 14, 13 and 10 amino acids, still activated the receptor. The shortest of these, the 10-amino-acid C-terminal fragment, became known as kisspeptin-10, or KP-10. It is not a separate discovery so much as the minimal active core of the larger peptide, the smallest piece that still fits the lock.
Why a cancer peptide ended up in reproductive biology
The deorphanising of GPR54 handed biologists a receptor and its ligand, but not yet a clear purpose. That arrived in 2003, and it reframed the whole field. Two independent groups, studying families with inherited failure to enter puberty, traced the condition to the same place: loss-of-function mutations in GPR54. Seminara and colleagues reported their findings in the New England Journal of Medicine, and de Roux and colleagues published in PNAS the same year. Both pointed to GPR54 signalling as essential for the normal onset of puberty and reproductive function.
The implication was hard to overstate. The receptor’s ligand, that repurposed cancer peptide, sat far upstream in the hormonal cascade that governs reproduction. Subsequent work placed kisspeptin’s action at the level of the GnRH (gonadotropin-releasing hormone) neurons in the hypothalamus, the small population of cells that sits at the top of that axis. A molecule first catalogued for stopping tumours had become a central research subject in how the reproductive system is switched on and regulated. Kisspeptin-10, as the compact active fragment, became a common tool for probing that receptor in laboratory studies.
Where the science stands
It is worth being honest about maturity. The naming origin is charming and well documented, and the broad arc, from 1996 metastasis suppressor to 2001 receptor ligand to 2003 reproductive regulator, is firmly established in the peer-reviewed record. Beyond that, much of what is written about kisspeptin-10 reflects active, ongoing research rather than settled conclusions. The peptide remains primarily an investigational compound studied in cell and animal models and in controlled clinical research settings. Its story is still being written, which is precisely what makes it interesting to follow.
For anyone tracing the history, the throughline is a reminder of how science actually moves: a chocolate-town pun attached to a cancer gene, an orphan receptor waiting for its match, and a chance discovery in a puberty clinic that connected the two.
→ Kisspeptin-10 Research Guide · COA available Kisspeptin-10 range
Research use only. Kisspeptin-10 is supplied by Vero Labs strictly as a research compound for in-vitro and laboratory research. It is not a medicine, supplement, or cosmetic, and is not intended for human or animal use, consumption, or any form of diagnostic or therapeutic application. Every batch is independently third-party lab-tested, with a published Certificate of Analysis (COA) available for verification.